FindTrial
Sign In

Clinical Study on Ahmed Valve for Neovascular Glaucoma in Pseudophakic Eyes

Clinical observation on the efficacy of posterior chamber Ahmed glaucoma valve implantation in treating neovascular glaucoma in pseudophakic eyes.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127661
Enrollment
Unknown
Registered
2026-07-04
Start date
2026-07-10
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular Glaucoma

Interventions

Ahmed valve implantation group:None

Sponsors

Tianjin Medical University Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients were included if they met the following criteria: clinical diagnosis of NVG; 2. Prior panretinal photocoagulation with significant regression or disappearance of iris neovascularization; 3. Previous phacoemulsification with IOL implantation; 4. Uncontrolled IOP (>21 mmHg) on maximally tolerated medical therapy requiring posterior chamber glaucoma valve implantation; 5. Complete follow-up data for at least 12 months.

Exclusion criteria

Exclusion criteria: 1. Patients were excluded if they had any of the following: active ocular infection, severe corneal opacity, or posterior segment lesions requiring urgent management; 2. A history of prior glaucoma surgery; 3. Severe corneal disease or active vitreoretinal lesions.

Design outcomes

Primary

MeasureTime frame
Postoperative intraocular pressure control situation;—

Secondary

MeasureTime frame
visual acuity;postoperative complications;—

Countries

China

Contacts

Public ContactAihua Liu

Tianjin Medical University Eye Hospital

liuaihua8136@126.com+86 22 86428705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026